List of converted stocks (Part 2) [List of converted stocks for Parabolic Signal]

List of sell conversion stocks: Market Code Stock Name Closing Price SAR Tokyo Stock Exchange Prime <1377> Sakata Seeds 3465 3475 <1379> Hokuto 1880 1914 <1766> Toyo Construction 11750 12700 <2207> Meito Sangyo 1960 2046 <2292> S FOODS 2903 2986

Fisco JapanJul 2 18:52 ET

List of cloud breakout stocks (Part 1) [Ichimoku Kinko Hyo Cloud Breakout Stock List]

List of recommended stocks in cloud market: Code, Company Name, Closing Price, Leading Span A, Leading Span B. Tokyo Stock Exchange Prime Board: <1871>, PS Construction, 1018, 1014, 1016.5. <1884>, Nippon Expressway, 1881, 1788.5, 1867.5. <2154>, Open UP, 2062, 2049.5, 2049. <2206>, Glico

Fisco JapanJul 2 18:49 ET

Nxera Pharma Co Achieves Key R&D Milestone in Collaboration With AbbVie; Secures $10 Million Payment

Nxera Pharma Co (TYO:4565) has achieved a significant R&D milestone in its multi-target discovery collaboration with AbbVie, earning Nxera a payment of $10 million, according to its filing on Thursday

MT NewswiresJun 27 07:58 ET

Esraline G, Carlet HD, and Daiyuuki are among them.

<6856> Horiba Manufacturing Co., Ltd. rose significantly by 265 to 12330. It seems that factory tours and IR Day were held the day before, which has led to evaluation materials. As for the state of semiconductors, it seems that the market for mass flow controllers is improving, and recovery is expected in the second half of the year. Sales of semiconductor-related products for China are also strong, and sales are moving higher than expected. In addition, there is an increasing expectation for future growth in the fields of hydrogen-related and life science. <3903> g

Fisco JapanJun 27 02:18 ET

Hot stocks digest (morning session): Carritt HD, Dai Organic Chemical, Technologies, etc.

Nexera <4565>: 1653 yen (+48 yen), a large continuous increase. In the drug discovery partnership with Abbvie for multiple targets for neurological diseases, it has announced that it has achieved an important milestone in the research stage. As a result, they will receive $10 million, most of which will be recognized as revenue in 2024, and the rest after 2025. Having achieved the first milestone in the drug discovery partnership, further progress in the project is expected in the future.

Fisco JapanJun 26 22:40 ET

Nexela---significantly extended, received milestones in drug discovery collaboration with AbbVie.

Nexella (4565) continues to surge. It has announced the achievement of an important milestone in the research stage of the drug discovery partnership with Abbvie, targeting multiple targets in neurological diseases. As a result, they will receive 10 million dollars, most of which will be recognized as revenue in 2024, and the rest in 2025 and beyond. With the achievement of the first milestone in the drug discovery partnership, further progress in the project is expected in the future.

Fisco JapanJun 26 22:20 ET